BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-209@pharmaconomics
DTSTAMP:20260707T004903Z
DTSTART;VALUE=DATE:20260729
DTEND;VALUE=DATE:20260730
SUMMARY:OTLK PDUFA — ONS-5010/LYTENAVA™ (bevacizumab-vikg)
DESCRIPTION:The FDA's approval decision on ONS-5010/LYTENAVA™ (bevacizumab-vikg) for wet AMD is due Jul 29\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/209
URL:https://www.pharmaconomics.com/e/209
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:OTLK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR